Pfizer Inc PFE

$28.89 +0.06 (0.21%)

Valuation

Market cap
164,668,784,000
Revenue TTM
$62,579,000,000
Net income TTM
$7,771,000,000
P/E (trailing)
9.45
P/E (forward)
9.47
Profit margin
12.42%
Debt to equity
0.70

Trading

Volume
21,598,700
Avg volume
33,090,832
Day's range
$28.62 – $28.99
Shares out
5,699,854,000
Stochastic %K
12%
Beta
0.31
Analysts
Hold
Price target
$30.53

Price

Company profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under...

Show more

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
212 733 2323
Website
https://www.pfizer.com
Address
66 Hudson Boulevard East, New York, United States

Latest news

Stocktwits

Djjazzyjeff Nov 15, 6:49 AM
$CYDY $PFE $MRNA this is pathetic and goes completely against CYDY asking investors to stop hounding the FDA. How sad is it to make a bad investment and then beg the FDA to give it some help so he can sell with less of a loss. Just sad. Oh I'm sure the FDA will be really interested in checking out a company he's invested in because he asked them to. What a loser. Last time morons hounded the FDA they got slapped with a letter explaining why the drug doesn't work lol.
0 replies
GTA_Terminal Nov 15, 3:13 AM
$PFE i guess the russian plague news didn’t stick like they wanted to. How is this ceo not in jail? So many died from their vaccine, misinformation, i remember they said exactly if you take the vaccine you cant spread it, and they lied it was pure marketing. Because they are protected by law they cant be sued. I remember.
0 replies
phoenixblaze Nov 15, 2:59 AM
$CYDY $PFE $MRNA https://markets.businessinsider.com/news/currencies/investor-richard-aronow-urges-federal-officials-to-review-leronlimab-as-early-cancer-results-draw-attention-1036764174
0 replies
UltraEgoVegeta Nov 15, 2:14 AM
$PFE positive news daily and it drops daily, just insane manipulations.
0 replies
SellasgpsCurativeBAT11 Nov 14, 4:12 PM
$ABBV $BMY $JNJ $PFE $SLS 👇 ✌️🙏❤️‍🩹
0 replies
SellasgpsCurativeBAT11 Nov 14, 4:07 PM
$SLS $JNJ $PFE $BMY $ABBV I expect an Immediate BO of Sellas after GPS Regal Pivotal Registrational Phase 3 Study Transformative Data. My # 1 Pick is $JNJ as $JNJ Executives have been openly touting Sellas GPS Breakthrough. 2. ABBV Ventoclax will become Obsolete after GPS FDA approval. 3. BMY Onureg will become Obselete after GPS FDA approval. 4. Pfizer CEO Bourla close ties to Sellas CEO Dr. Stergiou. ✌️🙏❤️‍🩹
0 replies
TensorTheta Nov 14, 2:20 PM
$PFE sitting at a valuation that keeps splitting opinions. Bulls see a value play with the pipeline catching up, bears see a value trap until growth actually shows up. Multiple looks cheap on paper but the market's clearly pricing in more than just a number. Worth watching how sentiment shifts next
0 replies
Techdamentals Nov 14, 1:38 AM
The S&P 500 fell 0.40% to 7,561.67 on Friday, November 13, 2026 but finished the week up 2.5%. One number from $PFE's latest report: revenue was $16.583 billion in the third quarter of 2026, down 0.4% from $16.654 billion, while research and development spending rose 18% to $3.016 billion. Is it growing, does it make money, can it pay its bills? The Techdamentals IV Calculator reads the fundamentals in plain English, from the company's own reported numbers. See the fundamentals for yourself and sign up for free. Educational, not advice. https://techdamentals.com/v3/PFE?ref=st
0 replies